ChemoCentryx is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics for autoimmune diseases, inflammatory disorders and cancer.

We have established one of the broadest pipelines of chemokine-based therapeutics in the biopharmaceutical industry based on our pioneering insight into the chemokine system, a complex network of chemokine (CHEMO-attractant cytoKINE) molecules (ligands) and receptors that work together to regulate inflammation.

ChemoCentryx has internally generated several clinical- and preclinical-stage compounds, each targeting distinct chemokine receptors and offering the potential to treat various diseases. ChemoCentryx's lead product candidate, Traficet-EN®, or CCX282, is a first-in-class, anti-inflammatory small molecule therapeutic targeting the CCR9 chemokine receptor for the treatment of inflammatory bowel disease (IBD). We are currently conducting a definitive dose-ranging study designed to support the potential registration in induction of response or remission in Crohn's disease.

We have initiated a Phase I clinical trial of CCX915 which targets the chemokine receptor CCR2. The CCR2 receptor is of central importance to inflammatory diseases, such as multiple sclerosis, Type II diabetes and atherosclerosis. CCX915 is one of several clinical-quality molecules inhibiting this receptor that have been identified by ChemoCentryx.

Each of our novel small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease while leaving the rest of the immune system intact. In addition, our orally-administered small molecules should offer convenience and compliance advantages, as well as lower costs of production over most biologic therapies.

ChemoCentryx is the only company focused exclusively on the discovery, development and commercialization of small molecule therapeutics that target the chemokine network. The company was founded by Thomas J. Schall, Ph.D., who participated in some of the earliest discoveries of chemokine system function and its activities. Since ChemoCentryx's founding, we have developed a set of proprietary drug discovery tools, known collectively as the EnabaLink® technology suite, specifically designed to unlock the chemokine system's complexity and to accelerate a productive drug discovery program. We have leveraged the EnabaLink drug discovery engine for the identification and optimization of each of our clinical and preclinical product candidates and we continue to apply these powerful research tools in our early-stage drug discovery efforts.

Key Management: